- Previous Close
6.25 - Open
6.44 - Bid 6.40 x --
- Ask 6.80 x --
- Day's Range
6.44 - 6.80 - 52 Week Range
2.80 - 12.00 - Volume
250,483 - Avg. Volume
980,539 - Market Cap (intraday)
7.133M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. It has a collaboration agreement with the National Cancer Institute for the use of OptiMAL for discovery of novel antibodies against targets selected by NCI. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
www.fusionantibodies.comRecent News: FAB.L
View More
Performance Overview: FAB.L
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FAB.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FAB.L
View MoreValuation Measures
Market Cap
6.56M
Enterprise Value
6.15M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.33
Price/Book (mrq)
6.19
Enterprise Value/Revenue
3.41
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-90.29%
Return on Assets (ttm)
-57.93%
Return on Equity (ttm)
-129.49%
Revenue (ttm)
1.8M
Net Income Avi to Common (ttm)
-1.59M
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
439k
Total Debt/Equity (mrq)
3.02%
Levered Free Cash Flow (ttm)
-585.25k